Zacks Research Weighs in on Allogene Therapeutics, Inc.’s FY2026 Earnings (NASDAQ:ALLO)

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – Analysts at Zacks Research issued their FY2026 earnings per share estimates for Allogene Therapeutics in a note issued to investors on Thursday, March 28th. Zacks Research analyst S. Ganoria forecasts that the company will post earnings per share of ($1.93) for the year. The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.72) per share.

A number of other equities research analysts also recently commented on the company. Citigroup assumed coverage on Allogene Therapeutics in a report on Friday, December 8th. They issued a “buy” rating and a $7.00 target price for the company. JMP Securities reissued a “market perform” rating on shares of Allogene Therapeutics in a report on Friday, January 5th. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Allogene Therapeutics in a report on Tuesday, March 19th. JPMorgan Chase & Co. reduced their target price on Allogene Therapeutics from $9.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, February 27th. Finally, Guggenheim downgraded Allogene Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, January 5th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $13.17.

Allogene Therapeutics Stock Up 0.2 %

Shares of NASDAQ ALLO opened at $4.47 on Friday. The stock has a fifty day moving average price of $4.42 and a 200 day moving average price of $3.51. Allogene Therapeutics has a 1-year low of $2.23 and a 1-year high of $6.89.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ALLO. McGlone Suttner Wealth Management Inc. purchased a new stake in Allogene Therapeutics during the 4th quarter worth about $27,000. EP Wealth Advisors LLC purchased a new stake in Allogene Therapeutics during the 3rd quarter worth about $34,000. Aaron Wealth Advisors LLC purchased a new stake in Allogene Therapeutics during the 4th quarter worth about $34,000. Axxcess Wealth Management LLC purchased a new stake in Allogene Therapeutics during the 4th quarter worth about $34,000. Finally, GTS Securities LLC purchased a new stake in Allogene Therapeutics during the 3rd quarter worth about $35,000. Hedge funds and other institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL.